People who are immunocompromised should receive Shingrix to reduce their risk of zoster.
People aged ≥50 years who are household contacts of a person who is, or is expected to become, immunocompromised are recommended to receive a zoster vaccine. This indirectly protects the immunocompromised household member from exposure to varicella-zoster virus. Shingrix is recommended.
Although Zostavax is a live virus vaccine, the rate of varicella-like rashes from Zostavax is very low. It is unlikely that vaccine-associated virus would be transmitted from a recently vaccinated person to a susceptible immunocompromised contact.24
If a vaccinated person develops a varicella- or zoster-like rash, they should:
cover the rash
avoid contact with people who are immunocompromised until the rash clears
